Genzyme reports positive top-line results of tower, a pivotal phase iii trial for aubagio (teriflunomide) in relapsing multiple sclerosis Full Text
Sanofi,

Sanofi and its subsidiary Genzyme announced top–line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once–daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis (MS). In the study, patients receiving teriflunomide 14 mg had a statistically significant reduction in annualized relapse rate and risk of sustained accumulation of disability. Analysis of the full TOWER data is ongoing and results will be presented at a forthcoming scientific meeting. This double–blind, multi–center trial enrolled 1,169 patients

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore